DEBIOPHARM, AURIGENE TO COLLABORATE ON ONCOLOGY TREATMENTS

The Switzerland-based Debiopharm Group, a biopharmaceutical development company specializing in oncology and serious medical conditions, and Aurigene Discovery Technologies, based in India, have signed a research agreement to identify and develop compounds for two innovative immuno-oncology targets.

Under the terms of the agreement, Aurigene will contribute its expertise in discovery and invivo optimization of lead compounds. Drug development expertise will be provided by Debiopharm. Debiopharm will pay Aurigene research milestones according to a pre-defined research plan and reimbursement of research costs upon achievement of a specific milestone.